Published in Neoplasia on February 01, 2011
Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2013) 1.40
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res (2012) 1.11
Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol Ther (2012) 1.04
Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia (2011) 1.00
Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol (2012) 0.92
Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration. Neoplasia (2012) 0.89
Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel. Neuro Oncol (2016) 0.87
The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp (Warsz) (2014) 0.87
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through ETA receptor. PLoS One (2014) 0.84
AICAR-Induced Activation of AMPK Inhibits TSH/SREBP-2/HMGCR Pathway in Liver. PLoS One (2015) 0.84
Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene (2015) 0.81
miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget (2016) 0.80
Cancer subclonal genetic architecture as a key to personalized medicine. Neoplasia (2013) 0.78
Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression. Oncotarget (2016) 0.78
The interconnectedness of cancer cell signaling. Neoplasia (2011) 0.75
Macitentan: An important addition to the treatment of pulmonary arterial hypertension. J Pharmacol Pharmacother (2015) 0.75
Validation of endothelin B receptor antibodies reveals two distinct receptor-related bands on Western blot. Anal Biochem (2014) 0.75
Targeting acid sphingomyelinase with anti-angiogenic chemotherapy. Cell Signal (2016) 0.75
Disrupting the endothelin and Wnt relationship to overcome chemoresistance. Mol Cell Oncol (2015) 0.75
β-arrestin1 at the cross-road of endothelin-1 signaling in cancer. J Exp Clin Cancer Res (2016) 0.75
Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer. Cell Death Differ (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Transduction of receptor signals by beta-arrestins. Science (2005) 9.87
Cancer of the ovary. N Engl J Med (1993) 4.53
Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev (1994) 4.19
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell (1994) 3.66
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med (2008) 3.35
The endothelin axis: emerging role in cancer. Nat Rev Cancer (2003) 2.81
Structural organization and chromosomal assignment of the gene encoding endothelin. J Biol Chem (1989) 2.77
Endothelins. N Engl J Med (1995) 2.52
Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol (2000) 2.35
Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res (2003) 2.32
Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell (2004) 2.29
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res (1985) 2.06
Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol (2000) 2.05
Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation (2000) 1.97
Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res (1996) 1.83
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol (2007) 1.80
Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res (2005) 1.69
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene (2004) 1.63
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2009) 1.59
Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem (2002) 1.56
Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst (1995) 1.55
Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res (2005) 1.47
Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res (1999) 1.46
Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol (2000) 1.44
Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther (2008) 1.43
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst (2006) 1.39
Growth regulatory properties of endothelins. Peptides (1993) 1.35
Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res (1997) 1.34
Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res (2001) 1.29
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res (2003) 1.24
New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov (2002) 1.22
Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol (1996) 1.21
Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol (2009) 1.20
Production of endothelin in human cancer cell lines. Cancer Res (1990) 1.19
Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res (2009) 1.19
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation (1999) 1.18
The endothelin axis in cancer. Int J Biochem Cell Biol (2008) 1.18
Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch (2001) 1.16
Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer (2001) 1.15
Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res (2000) 1.13
Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am J Respir Cell Mol Biol (2000) 1.11
Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther (2006) 1.08
Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate (2000) 1.07
Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia (2006) 1.07
Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension (2000) 1.07
Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res (1995) 1.05
Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer (2000) 1.03
Endothelin-1 and angiogenesis in cancer. Curr Vasc Pharmacol (2005) 1.03
Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor. Cancer Lett (2006) 1.02
The endothelin system in human glioblastoma. Lab Invest (2000) 1.00
A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer (2010) 1.00
Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol (1995) 0.99
Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer (2005) 0.99
Endothelin receptor B is required for the expansion of melanocyte precursors and malignant melanoma. Int J Dev Biol (2005) 0.99
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res (2007) 0.98
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res (2002) 0.98
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther (2007) 0.96
Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol (2000) 0.96
Endothelin receptor antagonism. Adv Pharmacol (1995) 0.96
Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia (2005) 0.95
Endothelin receptor antagonists in cancer therapy. Cancer Invest (2007) 0.95
Endothelin-1-induced pulmonary vasoreactivity is regulated by ET(A) and ET(B) receptor interactions. J Vasc Res (2007) 0.95
A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs (2006) 0.94
Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth. J Clin Invest (1995) 0.93
Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res (2004) 0.92
Endothelins in health and disease: an overview. Clin Exp Pharmacol Physiol (1999) 0.91
The endothelin family: an overview. J Cardiovasc Pharmacol (2000) 0.91
Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J (2000) 0.90
Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res (2008) 0.89
ETB receptors promote proliferation and migration of endothelial cells. J Cardiovasc Pharmacol (1995) 0.89
Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors. J Cardiovasc Pharmacol (1995) 0.87
Endothelin expression and responsiveness in human ovarian carcinoma cell lines. Eur J Cancer (1997) 0.84
Expression of endothelin(A) receptors in human gliomas and meningiomas, with high affinity for the selective antagonist PD156707. Neurosurgery (1998) 0.83
Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. Prostate (2005) 0.82
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Res Treat (2009) 0.81
ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation. Exp Biol Med (Maywood) (2006) 0.81
Therapeutic potential of endothelin receptor modulators: lessons from human clinical trials. Expert Opin Ther Targets (2009) 0.80
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep (2006) 0.80
Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) (2002) 0.80
Paracrine regulation of ovarian cancer by endothelin. Eur J Cancer (1999) 0.79
Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg (1998) 0.78
Endothelin receptor antagonists: current status and perspectives. J Cardiovasc Pharmacol (2000) 0.78
Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res (2002) 4.99
AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res (2010) 4.89
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell (2005) 3.96
Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell (2008) 3.95
Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell (2006) 3.28
Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol (2007) 3.03
The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer (2011) 2.87
Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev (2007) 2.78
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res (2005) 2.76
Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst (2002) 2.75
Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J (2006) 2.38
Tissue-specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res (2003) 2.32
Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res (2005) 2.16
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. J Natl Cancer Inst (2003) 2.16
An orthotopic nude mouse model of oral tongue squamous cell carcinoma. Clin Cancer Res (2002) 2.11
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol (2004) 2.10
Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia (2011) 1.78
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res (2007) 1.74
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res (2004) 1.68
Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. Clin Cancer Res (2003) 1.63
Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res (2003) 1.62
Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia (2010) 1.51
Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med (2007) 1.48
Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clin Cancer Res (2005) 1.47
Targeted induction of lung endothelial cell apoptosis causes emphysema-like changes in the mouse. J Biol Chem (2008) 1.44
Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A (2011) 1.41
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst (2006) 1.39
Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells. Oncogene (2002) 1.37
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2009) 1.37
Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet (2003) 1.35
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther (2007) 1.32
Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function. EMBO J (2007) 1.32
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res (2004) 1.32
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol (2002) 1.31
Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res (2005) 1.31
Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res (2004) 1.30
Finding the tumor copycat. Therapy fails, patients don't. Nat Med (2010) 1.29
Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. Cancer Res (2007) 1.29
Circulating monocytes expressing CD31: implications for acute and chronic angiogenesis. Am J Pathol (2009) 1.27
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res (2002) 1.27
Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res (2004) 1.26
Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol (2006) 1.26
Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer (2006) 1.25
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res (2003) 1.24
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res (2002) 1.23
Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol Oncol (2004) 1.23
ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway. Sci Signal (2010) 1.22
The brain microenvironment and cancer metastasis. Mol Cells (2010) 1.21
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J (2012) 1.15
Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells. Cancer Res (2004) 1.15
Decreased osteogenic differentiation of mesenchymal stem cells in alcohol-induced osteonecrosis. Clin Orthop Relat Res (2005) 1.13
Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget (2014) 1.13
Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate (2005) 1.13
Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res (2003) 1.13
Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain. Cancer Res (2009) 1.09
Generation of an immortalized astrocyte cell line from H-2Kb-tsA58 mice to study the role of astrocytes in brain metastasis. Int J Oncol (2009) 1.08
Leptin induces apoptosis via ERK/cPLA2/cytochrome c pathway in human bone marrow stromal cells. J Biol Chem (2003) 1.07
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res (2005) 1.05
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res (2008) 1.04
Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res (2007) 1.03
Formation of solid tumors by a single multinucleated cancer cell. Cancer (2011) 1.03
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res (2002) 1.02
Apoptotic cells initiate endothelial cell sprouting via electrostatic signaling. Cancer Res (2005) 1.02
Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. Clin Exp Metastasis (2008) 1.02
Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia (2008) 1.02
Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol (2002) 1.02
Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol (2006) 1.01
Downregulation of cell-free miR-198 as a diagnostic biomarker for lung adenocarcinoma-associated malignant pleural effusion. Int J Cancer (2013) 1.00
The biology of cancer metastasis. Semin Cancer Biol (2010) 1.00
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther (2007) 1.00
Transcription factor Dlx2 protects from TGFβ-induced cell-cycle arrest and apoptosis. EMBO J (2011) 0.99
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther (2002) 0.98
Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer. Korean J Urol (2013) 0.98
Continuous production of neo-fructooligosaccharides by immobilization of whole cells of Penicillium citrinum. Biotechnol Lett (2005) 0.98
Unbiased screening for transcriptional targets of ZKSCAN3 identifies integrin beta 4 and vascular endothelial growth factor as downstream targets. J Biol Chem (2008) 0.96
Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel. Cancer Res (2002) 0.96
Modification of the primary tumor microenvironment by transforming growth factor alpha-epidermal growth factor receptor signaling promotes metastasis in an orthotopic colon cancer model. Am J Pathol (2008) 0.96
Intratumoral heterogeneity for expression of tyrosine kinase growth factor receptors in human colon cancer surgical specimens and orthotopic tumors. Am J Pathol (2008) 0.95
Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice. Neoplasia (2005) 0.95
Stromal metalloproteinase-9 is essential to angiogenesis and progressive growth of orthotopic human pancreatic cancer in parabiont nude mice. Neoplasia (2007) 0.95
The biology of brain metastasis. Clin Chem (2012) 0.94